← Leaderboards
Seoyoung Catherine Kim
Brigham And Women'S Hospital
$5,029,016
Attributed
$5,029,016
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $954.4K · FY2010–22$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,029,016 · 5
By mechanism
R01$3,572,923 · 2
K23$680,311 · 1
R21$443,082 · 1
K24$332,700 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Daniel Hal Solomon$26,002,677
- Brian Thomas Bateman$6,450,805
- James A. Lederer$21,491,638
- Niteesh K Choudhry$10,267,534
- Krista F Huybrechts$10,039,261
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPharmacoepidemiologyDatabasesSafetyChronicInnovationLinkEnrollmentHospitalsRheumatologyRheumatismGuidelinesRheumatologistData SourcesAffectProspectivePrevalenceRandomized Controlled TrialsRegistriesComparative EffectivenessMedicareComputerized Medical RecordHealthcareRisk Factors
Grant awards (18)
Mentoring Patient-Oriented Pharmacoepidemiologic Research in Rheumatic Diseases$166,296
K24 · FY2022 · AR · contact PI
Comparative Effectiveness of Treat-To-Target Approach versus Routine Care in Management of Gout$407,634
R01 · FY2021 · AR · contact PI
Mentoring Patient-Oriented Pharmacoepidemiologic Research in Rheumatic Diseases$166,404
K24 · FY2021 · AR · contact PI
Comparative Effectiveness of Treat-To-Target Approach versus Routine Care in Management of Gout$435,018
R01 · FY2020 · AR · contact PI
Comparative Effectiveness of Treat-To-Target Approach versus Routine Care in Management of Gout$492,573
R01 · FY2019 · AR · contact PI
Use and safety of opioids in patients undergoing total joint replacement$461,850
R01 · FY2019 · AR · contact PI
Use and safety of opioids in patients undergoing total joint replacement$461,850
R01 · FY2018 · AR · contact PI
Use and safety of opioids in patients undergoing total joint replacement$249,087
R01 · FY2018 · AR · contact PI
Use and safety of opioids in patients undergoing total joint replacement$461,850
R01 · FY2017 · AR · contact PI
Xanthine oxidase inhibitors and risks of myocardial infarction and diabetes$202,016
R21 · FY2017 · AR · contact PI
Use and safety of opioids in patients undergoing total joint replacement$603,061
R01 · FY2016 · AR · contact PI
Xanthine oxidase inhibitors and risks of myocardial infarction and diabetes$241,066
R21 · FY2016 · AR · contact PI
Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.$135,726
K23 · FY2014 · AR · contact PI
Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.$135,726
K23 · FY2013 · AR · contact PI
Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.$890
K23 · FY2013 · AR · contact PI
Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.$135,726
K23 · FY2012 · AR · contact PI
Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.$135,726
K23 · FY2011 · AR · contact PI
Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.$136,517
K23 · FY2010 · AR · contact PI